Skip to main content

AI-Assisted Screening Tool Speeds Trial Eligibility Determination

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 24, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, Feb. 24, 2025 -- Compared with manual screening, an artificial intelligence (AI)-assisted patient screening tool can improve the rate of eligibility determination and enrollment for randomized clinical trials, according to a research letter published online Feb. 17 in the Journal of the American Medical Association.

Ozan Unlu, M.D., from Mass General Brigham in Somerville, Massachusetts, and colleagues developed the Retrieval Augmented Generation Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review (RECTIFIER) large language model tool and tested it in a prospective, blind, randomized clinical trial within the Mass General Brigham Health System. The trial was completed within an ongoing heart failure implementation trial and included 4,476 patients who were randomly assigned. The primary outcome was time to trial eligibility determination, which was assessed using a survival analysis framework.

The researchers found that compared with patients screened manually, patients screened with the AI-assisted method achieved the primary end point of eligibility determination significantly more quickly (subdistribution hazard ratio [HR], 1.78). The eligibility rate was 20.4 and 12.7 percent for the AI-assisted screening and manual screening methods, respectively. At the end of the trial, there were 35 and 19 enrollments (1.6 and 0.9 percent, respectively) using the AI-assisted screening and manual screening methods (subdistribution HR, 1.79).

"Implementing AI-assisted screening tools like RECTIFIER enhances clinical trial efficiency and expedites the screening and recruitment process, which may lead to faster trial completion and earlier access to novel therapies for patients," the authors write.

Several authors disclosed ties to relevant organizations.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections

WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...

AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.